Adoram Therapeutics is an Swiss-based biotech startup focused on developing cutting-edge therapeutic assets. Our pipeline includes two differentiated preclinical-stage allosteric modulators, backed by compelling preclinical proof-of-concept (PoC) data from ex vivo human and in vivo mouse studies.

Asset 1 is a negative allosteric modulator of A2AR, a best-in-class immuno-enhancer with excellent potential for immunotherapy in solid tumors. This asset is poised to synergize with existing and emerging blockbuster therapies, including immune checkpoint blockade (ICB) monoclonal antibodies, to offer enhanced efficacy in cancer treatments.

Asset 2 is a first-in-class positive allosteric modulator of A2AR, with the potential to transform the treatment of various inflammatory, immunological, and metabolic diseases. This asset has wide-ranging therapeutic applications aimed at improving patient outcomes across multiple disease areas.

Our allosteric approach to drug development offers a safer, more targeted, and effective alternative to conventional 'orthosteric' small molecules. At Adoram Therapeutics, we are committed to developing the next generation of small molecule medicines that improve the lives of patients worldwide.

Adoram Therapeutics

Org chart

Teams

Offices